Among oncogenic KRAS mutations, many G12 and G13 mutations only significantly impair GAP-mediated hydrolysis and only Q61 mutations reliably impair intrinsic GTP hydrolysis, leading to the sustained activation of effector pathways and driving tumor growth (12, 13). This evidence concerns the gene KRAS and neoplasm.